XSHE
300871
Market cap640mUSD
Oct 09, Last price
20.91CNY
1D
-1.60%
1Q
-7.52%
IPO
-60.04%
Name
Wuhan Hvsen Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.
Key people
Jie Han
General Manager · since 2025
Jinbin Huang
Deputy General Manager · since 2020
Shuo Li
Deputy General Manager · since 2022
Yanshu Wu
Deputy General Manager
Kaijie Yang
Chief Financial Officer, Deputy General Manager · since 2024
Qingfeng Wang
Secretary of the Board · since 2022
Zexiang Liu
Director · since 2022
Weiyuan Zhang
Chairman of the Board · since 2023
Jian Zhou
Staff Elected Director · since 2025
Mingdong Ran
Independent Director · since 2024
Ming Wang
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||